The markets refuse to forgive Infinity
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Seeking alpha in PI3K inhibition
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
